Hester Biosciences Ltd reported a 17% profit growth for FY25 and a 30% increase in Q4, alongside a 12% growth at the divisional level despite flat overall revenue due to a prior year's one-time export sale. This was discussed in their earnings conference call held on 9 May 2025.